NCT03309800

A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 168 (actual)
• Sponsor: Hanlim Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Placebo in acute bronchitis patients. Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response, The satisfaction of the subject, Total usage of Acetaminophen

Conditions

• Acute Bronchitis

Interventions

Type	Name	Description
DRUG	HL301	HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
DRUG	HL301(Placebo)	HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment

Timeline

• Start date: 2017-03-29
• Primary completion: 2017-08-17
• Completion: 2017-08-28
• First posted: 2017-10-16
• Last updated: 2017-10-16

Locations

1 site across 1 country: South Korea